Most Read

Earlier, ARO-APOC3 received Orphan Drug designation from the FDA and the European Union. ARO-APOC3 is the firm’s investigational RNAi therapeutic targeting apolipoprotein C-III (APOC3). It is being developed

The oral androgen receptor inhibitor (ARi) darolutamide already received approval in China to treat non-metastatic castration-resistant prostate cancer (nmCRPC) patients at high risk of developing metastatic disease. The

With this approval, the firm intends to introduce Xerava in the Chinese market in the third quarter of this year. Xerava is a new fully synthetic, broad-spectrum, fluorocycline

The Series A round was co-led by Novartis Venture Fund and Sofinnova Partners and has seen participation from Pfizer Ventures, Mission BioCapital, Gimv, Pureos, Bristol Myers Squibb, Eli

If given approval, Nucala will become the first targeted anti-Interleukin-5 (IL-5) treatment in the country for adult and adolescent patients with SEA. A first-in-class monoclonal antibody to target

This funding round was primarily subscribed by current shareholders exercising their rights of first refusal. Leveraging this fund raise, Evergreen is launching a new business unit, called Evergreen

The deal was announced on 23 October 2022. Sumitovant has acquired all outstanding shares of Myovant it did not own through the all-cash deal. Following the completion of

The financing round, which brings the total funds raised by the firm to $143.5m, was led by EQT Life Sciences, investing from Droia Ventures, Sanofi Ventures and the

F-star is being acquired for a total cash consideration of approximately $161m or $7.12 per share. Currently, F-star is undertaking Phase II trials in Europe and the US.